He YL, et al. - The researchers examined the safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. For the treatment of acute hepatitis C virus (HCV)-infected patients who were undergoing end-stage renal disease and were on haemodialysis, a half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (60 mg once daily) was suitable.